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Inhibition of Fast Axonal Transport by Pathogenic SOD1
Involves Activation of p38 MAP Kinase
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Abstract
Dying-back degeneration of motor neuron axons represents an established feature of familial amyotrophic lateral sclerosis
(FALS) associated with superoxide dismutase 1 (SOD1) mutations, but axon-autonomous effects of pathogenic SOD1
remained undefined. Characteristics of motor neurons affected in FALS include abnormal kinase activation, aberrant
neurofilament phosphorylation, and fast axonal transport (FAT) deficits, but functional relationships among these
pathogenic events were unclear. Experiments in isolated squid axoplasm reveal that FALS-related SOD1 mutant
polypeptides inhibit FAT through a mechanism involving a p38 mitogen activated protein kinase pathway. Mutant SOD1
activated neuronal p38 in mouse spinal cord, neuroblastoma cells and squid axoplasm. Active p38 MAP kinase
phosphorylated kinesin-1, and this phosphorylation event inhibited kinesin-1. Finally, vesicle motility assays revealed
previously unrecognized, isoform-specific effects of p38 on FAT. Axon-autonomous activation of the p38 pathway
represents a novel gain of toxic function for FALS-linked SOD1 proteins consistent with the dying-back pattern of
neurodegeneration characteristic of ALS.
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aspects relevant to ALS were difficult to identify, because mSOD1
can have multiple adverse effects on motor neurons [1]. Although
motor neuron death represents the final outcome of ALS,
pathological observations from ALS patients and transgenic mice
expressing SOD1 mutants indicate that altered synaptic and
axonal function occur much earlier than cell death, consistent with
the ‘‘dying-back’’ pattern common to distal axonopathies [6].
However, little is known about molecular mechanisms underlying
axonal degeneration in ALS [7]. Most FALS models rely on
overexpression of mSOD1, making it impossible to distinguish
pathogenic events in axonal compartment from those in neuronal
cell bodies [7]. A major challenge in ALS research is the
identification of disease-specific effects of mSOD1 in axons.
Transgenic expression of mSOD1 in mice (G93A-SOD1 mice)
triggers motor neuron disease closely resembling human ALS [8],
despite normal levels of endogenous SOD1. Pathological changes
in motor neurons of mSOD1 transgenic mice include abnormal

Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive, adult-onset,
neurodegenerative disease mainly affecting function and survival
of motor neurons [1]. Most ALS cases are sporadic (SALS) with no
identified genetic defect, but 5–10% result from mutations in
specific alleles causing familial forms of ALS (FALS). Genes
associated with FALS encode proteins of diverse structure and
function, including superoxide dismutase 1 (SOD1; reduction of
superoxide radicals and redox signaling), an intronic expansion in
the gene C9orf72 [2,3], nucleic acid binding proteins TDP-43 and
FUS/TLS [4], VAPB (vesicle trafficking), senataxin (helicase), and
dynactin (cytoplasmic dynein accessory protein). Clinical phenotypes of SALS closely resemble FALS variants, suggesting possible
overlapping pathogenic pathways between FALS and SALS [1].
Mutations in the SOD1 gene are the best-characterized cause of
FALS [5]. Genetic evidence indicates that pathogenic effects of
mutant SOD1 (mSOD1) reflect a toxic gain of function, but
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mice were compared [27]. Conventional kinesin is a heterotetramer composed of two heavy chains (kinesin-1, KHC) and two
light chains (KLC) [24]. Antibodies recognizing KHCs effectively
immunoprecipitated the conventional kinesin holoenzyme from
both WT-SOD1 and G93A-SOD1 mouse spinal cord lysates
(Fig. 1f). Under these conditions (see methods), KLCs coprecipitated with KHC (kinesin-1) [24–26]. However. antiSOD1 antibodies failed to detect SOD1 in kinesin-1 immunoprecipitates. The lack of co-immunoprecipitation indicated that
inhibitory effects of mSOD1 proteins on anterograde FAT did
not result from direct interactions between mSOD1 and conventional kinesin, consistent with previous reports [28].

activation of protein kinases [9,10], increased neurofilament
phosphorylation [11], synaptic function abnormalities [12] and
deficits in fast axonal transport (FAT) [13–15]. However, relevant
pathogenic targets for activated kinases were not identified, and
mechanisms linking kinase activation to axonal and synaptic
degeneration were unknown.
We report here that pathogenic mSOD1 selectively inhibited
fast axonal transport (FAT) in isolated axoplasm by a mechanism
involving activation of axonal p38 mitogen-activated protein
kinases (MAPKs) and kinesin-1 phosphorylation. Accordingly,
activation of p38 MAPK was also observed in spinal cord of
G93A-SOD1 mice. Moreover, detection of p38-phosphorylated
serines 175/176 within kinesin-1, which impaired translocation of
kinesin-1 along axonal microtubules, provides a molecular basis
for inhibition of FAT by mSOD1. Axon-autonomous effects of
mSOD1 provide a mechanism linking increased kinase activity,
heightened neurofilament phosphorylation, and FAT deficits in
FALS. Activation of the p38 MAPK pathway and consequent
inhibition of FAT represents a toxic gain of function mechanism
associated with pathogenic forms of SOD1.

Pathogenic SOD1 increases phosphorylation of
neurofilaments and kinesin subunits in axoplasm
Our previous work showed that mutant proteins associated with
neurodegenerative diseases can affect FAT by activating axonal
kinases involved in the regulation of FAT [29]. Moreover, various
studies reported abnormal activation of protein kinases in spinal
cords of ALS patients and ALS mouse models [9], but relevant
phosphorylated targets and pathways mediating kinase activation
were not defined. To determine whether mSOD1 activated
kinases, we performed metabolic labeling in isolated axoplasm. To
control for variation in basal kinase activity, two ‘‘sister’’ axons
were dissected from each squid and extruded (Fig. S1). Labeling
with c–32P-ATP, one axon was perfused with WT-SOD1 and the
contralateral ‘‘sister’’ axon with G93A-SOD1. After 50 min,
axoplasms were analyzed by SDS-PAGE and autoradiography
(Fig. 2a), revealing two predominant 32P-labelled polypeptides at
<220 kDa and .400 kDa. An antibody against mammalian NFH
(SMI31) that recognizes squid neurofilaments confirmed identification of these bands as NF220 and high molecular weight NF
aggregates (HMW) [30]. NF220 is a major phosphoprotein in
squid axoplasm, homologous to mammalian NF heavy chain
(NFH) [31]. Consistent with reports of increased NFH phosphorylation early in ALS [11,32], HMW and NF220 phosphorylation
increased in axoplasms perfused with G93A-SOD1, compared to
WT-SOD1 (Fig. 2a). Phosphorimager analysis revealed an
approximately 2-fold increase in overall NF220 phosphorylation
(n = 4; p#0.0284 in a paired t-test; Fig. 2b). The effect required
structural integrity of axoplasms, because adding mSOD1 and
32
P-ATP to homogenized axoplasms did not affect NF220
phosphorylation (not shown). This observation was consistent
with previous observations that mechanical disruption of the
axoplasm and nerve tissue alters the activity of kinases, phosphatases and chaperones, presumably due to altered compartmentation/organization of the various components [33].
To determine effects of mSOD1 on kinesin-1 phosphorylation,
‘‘sister’’ axoplasms were perfused with WT-SOD1 or G93ASOD1and c232P-ATP (Fig. S1). Kinesin-1 was immunoprecipitated from axoplasm lysates, and incorporation of radiolabeled P32
analyzed by Phosphorimager [34]. Both KHC and KLC subunits
of conventional kinesin incorporated 32P (Fig. 2c) [35–38].
Significantly, kinesin-1 phosphorylation increased by approximately 30% in axoplasms perfused with G93A-SOD1, relative to
WT-SOD1 (Fig. 2d) without statistically significant changes in
KLC phosphorylation. This increase likely represents an underestimation of changes at a given phosphorylation site, since some
kinesin-1 residues are constitutively phosphorylated [38,39].
Together, these experiments indicated that mSOD1 proteins
increased NF and kinesin-1 (KHC) phosphorylation through
activation of endogenous axonal kinases.

Results
Pathogenic SOD1 mutant proteins selectively inhibit
anterograde fast axonal transport
Although the axonal compartment is a critical pathogenic target
in ALS [6], axon-specific effects of mSOD1 have not been
previously defined [7]. Deficits in both anterograde and retrograde
FAT were reported in FALS [16,17], but the diverse effects of
mSOD1 on gene transcription, microglial activation and apoptotic
pathways left unclear whether these FAT deficits were a
consequence or cause of these events [5,18]. To evaluate axonautonomous effects of pathogenic SOD1 we assayed FAT in
isolated squid axoplasm, which lacks transcription, protein
synthesis machinery, and glial components [19]. This ex vivo
experimental system allows quantitative analysis of FAT for
membrane-bounded organelles (MBOs) in both anterograde
(conventional kinesin-dependent) and retrograde (cytoplasmic
dynein-dependent) directions. The lack of plasma membrane in
the isolated axoplasm preparation facilitates quantitative evaluation of how pathogenic proteins affect FAT [20].
Purified (.95%), recombinant wild type SOD1 (WT-SOD1)
and three FALS-linked SOD1 mutants (G93A, G85R, and H46R)
were prepared as described previously [21]. SOD1 was perfused at
5 mM and FAT analyzed by video-enhanced microscopy for
50 minutes (Fig. 1). SOD1 is an abundant protein in mammalian
brain (present at mM levels) [22]. Although 5 mM was used
standardly to facilitate comparisons, similar effects were observed
with lower concentrations of pathogenic SOD1 (0.1–0.4 mM, not
shown) [23]. Perfusion of WT-SOD1 had no effect on either
direction of FAT (Fig. 1a). In contrast, perfusion of G93A-SOD1
selectively inhibited anterograde FAT (Fig. 1b). Similar results
were obtained with G85R-SOD1 and H46R-SOD1 mutant
variants (Figs. 1c–d). Quantitative analysis indicated that all
mSOD1 proteins tested significantly inhibited anterograde, but
not retrograde FAT (Fig. 1e). Selective inhibition of anterograde
FAT by mSOD1 proteins ruled out effects on microtubule
integrity, steric interference by potential SOD1 aggregates and
ATP deficits, which would compromise both anterograde and
retrograde transport.
To evaluate possible physical interactions of conventional
kinesin with mSOD1, co-immunoprecipitation studies were
undertaken [24–26]. Spinal cord lysates from transgenic mice
expressing wild type SOD1 (WT-SOD1 mice) or G93A-SOD1
PLOS ONE | www.plosone.org
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Figure 1. FALS-linked mutant SOD1 proteins selectively inhibit anterograde, conventional kinesin-dependent FAT. (a–d) Vesicle
motility assays in isolated squid axoplasm. Individual velocity (mm/sec) rate measurements (arrowheads) are plotted as a function of time (minutes).
Dark arrowheads and lines represent anterograde, conventional kinesin-dependent rates. Grey arrows and lines represent retrograde, cytoplasmic
dynein-dependent rates. Perfusion of WT-SOD1 protein (a) in axoplasm shows no effect on either direction. In contrast, perfusion of G93A-SOD1
specifically inhibits anterograde, but not retrograde FAT (b). Similar results were obtained after perfusion of SOD1-G85R (c) and SOD1-H46R (d). n:
number of experiments. (e) 30 to 50 minutes after perfusion, anterograde FAT rates were significantly lower in axoplasms perfused with mSOD1, than
in axoplasms perfused with either WT-SOD1 (#: p#0.01) or control buffer (not shown). All pathogenic SOD1 proteins tested had no effect on
retrograde FAT. (f) Kinesin-1 (KHC IPP) was immunoprecipitated from spinal cord lysates of transgenic mice expressing either WT-SOD1 (WT) or G93ASOD1 (G93A). An aliquot of lysate (Input) was included as positive control. Immunoblots using anti-kinesin-1 antibody (KHC) demonstrated effective
immunoprecipitation from lysates, regardless of genotype. Specificity was confirmed by the absence of kinesin-1 on control immunoprecipitates with
non-immune mouse IgG (Ctrl IPP). Immunoblot with an anti-SOD1 monoclonal antibody (D3H5) failed to detect SOD1 in kinesin-1
immunoprecipitates, suggesting that neither WT SOD1 nor G93A-SOD1 interact directly with kinesin-1.
doi:10.1371/journal.pone.0065235.g001

analysis showed that anterograde FAT rates for axoplasms coperfused with G93A-SOD1 and either CREBp, SP600125, or
MW189 were significantly lower than in axoplasms with WTSOD1. Anterograde FAT rates for axoplasms with G93A-SOD1
and either SB203580 or MW069 were indistinguishable from
controls (Fig. 3f). These data indicate that inhibition of anterograde FAT by mSOD1 mutants depends upon activation of
axonal p38 in the axoplasm preparation.
We also evaluated activation of various NF kinases in isolated
axons using biochemical methods. ‘‘Sister’’ axoplasms were
perfused with WT-SOD1 or G93A-SOD1 (Fig. S1). After
50 min, axoplasms were analyzed by immunoblotting. Antibodies
recognizing phosphorylated forms of GSK3 (Ser9), ERK
(Thr202/Tyr204) and JNK (Thr183/Tyr185) showed no differences in activity between WT-SOD1 and G93A-SOD1-perfused
axoplasms (Fig. 4a). In contrast, antibodies against active p38
phosphorylated at Thr180/Tyr182 (p-p38), revealed increased
p38 activity in axoplasms perfused with G93A-SOD1, compared
to WT-SOD1 (Fig. 4a). G93A-SOD1 induced an approximately 4fold increase in p38 activation, as compared to WT-SOD1 (n = 8;
Fig. 4b). Increased p38 phosphorylation was also seen with G85RSOD1-perfused axoplasms (Fig. 4c) [46]. Effects of mSOD1
proteins on p38 activity were consistent with those induced by an

p38 MAPK mediates inhibition of FAT induced by
pathogenic SOD1
To identify specific kinases involved, we co-perfused axoplasms
with G93A-SOD1 and specific inhibitors of NF kinases, including
GSK3 and MAP kinases [40]. Previously, these approaches
allowed identification of kinase-dependent pathogenic pathways
activated by other neuropathogenic proteins. For example,
selective inhibition of anterograde FAT by pathogenic tau is
prevented by co-perfusion with GSK3 inhibitors [41], but effects
of pathogenic androgen receptor [34] and huntingtin [26] on FAT
are blocked by JNK inhibitors.
Co-perfusion of G93A-SOD1 with either CREBp (a competitive inhibitor of GSK3) [38] or SP600125 (an inhibitor of JNK
kinases) [42] (Fig. 3a, b) failed to block mSOD1 effects on
anterograde FAT. In contrast, SB203580 completely protected
(Fig. 3c). SB203580 is a selective inhibitor of p38 MAPK [43] and
JNK2/3 [44]. Effects of mSOD1 on anterograde FAT was also
prevented by MW01-2-069SRM (MW069), a highly selective
pharmacological inhibitor of p38 structurally unrelated to
SB203580 [45] (Fig. 3d). In contrast, MW01-6-189WH
(MW189), a structural analog of MW069 that is inactive as a
p38 MAPK inhibitor, did not protect (Fig. 3e). Quantitative
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and ERK showed similar levels of activation for these kinases,
regardless of genotype (not shown), but as seen previously [47–49],
and in axoplasm (Fig. 4a), p38 phosphorylation increased in spinal
cord lysates of G93A-SOD1, relative to those from WT-SOD1
and naı̈ve mice. Interestingly, spinal cord lysates from WT-SOD1
mice showed a slight increase in p38 activation relative to naı̈ve
mice, suggesting a possible role for WT-SOD1 in modulating the
p38 MAP kinase pathway or overexpression-related misfolding of
WT-SOD1 [23]. SMI32 antibodies recognizing a dephosphorylated NF heavy chain (NFH) epitope showed reduced immunoreactivity in lysates from G93A-SOD1 relative to naı̈ve and WTSOD1 mice, indicating increased NFH phosphorylation at this site
in G93A-SOD1 mice. Phosphorylation-dependent SMI31 antibodies mapping to a different NFH epitope showed similar
immunoreactivity in naı̈ve, WT-SOD1 and G93A-SOD1 mice,
indicating that total NF levels and phosphorylation at the SMI31
epitope were unchanged. Anti-kinesin-1 (KHC) antibodies further
confirmed similar protein loading. SMI32 antibodies recognize an
NF220 epitope targeted by MAPKs, whereas SMI31 antibodies
are not sensitive to MAPK activity [34]. Immunoblots of
axoplasms and transgenic mice spinal cords, as well as coperfusion experiments all indicated that pathogenic mSOD1
activate a p38 MAPK pathway. The increased ability of mSOD1,
but not WT-SOD1 to increase axonal p38 kinase activity
represents a toxic gain of function for mSOD1 consistent with
autosomal dominant inheritance of mSOD1-related FALS.

p38 MAPK activation in neurons of presymptomatic
G93A-SOD1 transgenic mice
To determine whether p38 MAPK is activated within spinal
cord motor neurons of mice expressing mSOD1, we compared age
matched naı̈ve mice to presymptomatic (60 days old) transgenic
mice overexpressing either WT-SOD1 or G93A-SOD1 using
antibodies recognizing p-p38 and NeuN, a neuron-specific marker
(Fig. 5). Spinal cords from naı̈ve mice (endogenous) showed low
phospho-p38 immunoreactivity (Fig. 5a, d) consistent with low
basal activation of p38 in normal tissue. Introduction of a WTSOD1 transgene slightly increased phospho-p38 immunoreactivity
(Figs. 5b, e and 4d), but there was minimal co-localization of
phospho-p38 and NeuN in the ventral horn (Fig. 5g–i), with most
p-p38 immunoreactivity mapping regions that lack neuronal cell
bodies, such as white matter. In contrast, phospho-p38 increased
significantly in both white and grey matter of G93A-SOD1
transgenic spinal cord (Fig. 5c, f, and 4d) and showed a significant
increase in co-localization of p-p38 and NeuN indicative of
neuronal activation (Fig. 5g-i). This is consistent with previous
reports documenting activated p38 in motor neurons of mouse
models of FALS, as well as in spinal cords from both SALS and
FALS human patients [10,47,49]. Increased activation of p38
MAPK in neurons from 60 d old mice, before signs of motor
neuron disease suggests an early step in FALS pathogenesis rather
than an inflammatory response.

Figure 2. Pathogenic SOD1 increases neurofilament phosphorylation. Phosphorylation of squid neurofilaments (NF) in isolated
‘‘sister’’ axoplasms (see Methods) was analyzed using metabolic labeling
experiments with 32P-c-ATP. (a) Coomassie Blue staining (CB) shows
similar levels of perfused WT-SOD1, G93A-SOD1 and total axoplasmic
proteins. Immunoblot analysis (WB) with the NFH antibody SMI-31
confirmed the identity of major phosphorylated bands as NF220 and
HMW, major NF subunits in squid axoplasm [30]. Short (S) and long (L)
exposure of autoradiograms (32P) show increased phosphorylation of
NF220 and HMW NF subunits in axoplasms perfused with G93A-SOD1,
compared to WT-SOD1. (b) Quantitation of squid NF phosphorylation
showed .70% increase in G93A-SOD1 treated axoplasms, compared to
those treated with WT-SOD1 (p#0.01 (#) in a paired t-test). (c) In
parallel experiments, kinesin-1 was immunoprecipitated from axoplasms labeled with c-32P-ATP in the presence of WT-SOD1 or G93ASOD1. Both heavy (KHC) and light (KLC) chains of conventional kinesin
were phosphorylated. (d) The ratio of counts for G93A-SOD1/WT-SOD1
indicates that KHC labeling increased 31% in G93A-SOD1 axoplasms,
compared to WT-SOD1 (significant at p#0.05 by paired t-test, #). KLC
phosphorylation increased by 15%, but was not statistically significant
(p = 0.123). n = 7.
doi:10.1371/journal.pone.0065235.g002

Isoform-specific effects of p38 on FAT

oxidized form of WT-SOD1, which mimics toxic properties of
FALS-linked SOD1 mutants [23].
To validate these observations in mammalian FALS-affected
neurons, we examined both NF phosphorylation and kinase
activity in transgenic mice expressing either human WT-SOD1 or
G93A-SOD1, as well as in naı̈ve, non-transgenic mice with only
endogenous mouse SOD1. Spinal cord lysates were prepared from
age-matched, presymptomatic (50d old) non-transgenic (naı̈ve),
WT-SOD1 (WT) and G93A-SOD1 (G93A) mice and processed
for immunoblots (Fig. 4d). Phosphoantibodies against GSK3, JNK

PLOS ONE | www.plosone.org

Experiments in axoplasm suggested that pathogenic mSOD1
activate axonal p38 to inhibit anterograde FAT. but did not
identify specific p38 isoforms. The complement of p38 isoforms
expressed in squid is unknown, but four p38 genes exist in
mammals (p38a, p38b, p38c, and p38d) [50], which differentially
contribute stimulus- and cell-specific responses mediated by the
p38 MAPK pathway. Of these, p38a and p38b are the major
isoforms in the mammalian CNS, and in spinal motor neurons of
the ventral horn, which are affected in ALS [51] (Fig. S2). Due to
high homology conservation of the activation loop, anti p-p38
4
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Figure 3. p38 MAPK mediates the inhibition of anterograde FAT by pathogenic SOD1. (a–e) Co-perfusion of G93A-SOD1 with either
CREBp (a competitive inhibitor of GSK3) (a) or SP600125 (a pharmacological inhibitor of JNK) (b) did not block effects of G93A-SOD1 on anterograde
FAT, but co-perfusion with SB203580 (an inhibitor of p38 and JNK2/3) completely blocked effects of mutant G93A-SOD1 on anterograde FAT (c).
MW01-2-069SRM (MW069) [45], a selective inhibitor of p38a structurally unrelated to SB203580 also blocked inhibition of FAT (d), but an inactive
MW069 analog MW01-6-189WH (MW189) did not (e). n = number of experiments. (f) Quantitation of a–e shows that SB203580 (SB) and MW069
compounds, but not CREBp, SP600125 (SP) or MW189 compounds blocked the effects of G93A-SOD1 on anterograde FAT (# indicates different from
WT SOD1 at p#0.001 by pooled t-test). Plots show the mean, standard deviation, maximum and minimum of FAT rates recorded 30–50 min for each
experimental condition.
doi:10.1371/journal.pone.0065235.g003

a recombinant kinesin-1 construct containing the first 584 amino
acids of kinesin-1C (KHC584) (Fig. 7a), and native kinesin-1
immunoprecipitated from mouse brain (Fig. S3). A dually
phosphorylated peptide corresponding to amino acids 174–188
in kinesin-1C was identified using liquid chromatography tandem
mass spectrometry (LC/MS/MS). Tandem mass spectrometry
analysis (MS/MS) by collision-induced dissociation further
mapped phosphorylation sites to serines 175 and 176 (Fig. 7b
and Fig. S4 and S5), consistent with the substrate preference of
MAPKs for serines preceded by a proline, and with phosphorylation of Ser176 by JNK3. Sequence homology analysis showed
Ser175 and 176 are conserved among squid, mouse and human
kinesin-1s (Fig. 7c and Fig. S4 and S5). These experiments
identified kinesin-1 as a novel p38a substrate, and mapped serines
175/176 as p38a acceptor residues.

antibodies cannot distinguish between p38 isoforms, prompting us
to evaluate functional effects of p38a and p38b on FAT in
axoplasm (Fig. 6). Specific enzymatic activities of recombinant p38
isoforms were normalized using in vitro kinase assays with ATF-2 as
substrate (not shown), allowing for perfusion of p38a and p38b at
similar specific activities into axoplasm. As observed with G93ASOD1, p38a (10 nM) selectively inhibited anterograde FAT
(compare Figs. 1b and 6a). Effects of p38a on FAT were similar
to G93A-SOD1 (Fig. 6c). In contrast, perfusion of p38b (50 nM)
inhibited both anterograde and retrograde FAT (Fig. 6b–c). The
relative selectivity of MW069 for p38a, and differential effects of
p38a and p38b on FAT suggest that p38a may mediate the
inhibition of FAT by mSOD1 in axoplasm. However, some
upstream kinases for activation of p38a also activate p38b [52], so
we cannot rule the possibility that mSOD1 activates both p38a
and p38b in mammalian axons. Consistent with this possibility,
sciatic nerve ligation experiments in G93A mice reported
inhibition of both anterograde and retrograde FAT (data not
shown) [14,28,53,54].

Ser175-176 phosphorylation inhibits kinesin-1
translocation
Serines 175/176 are in a surface loop of the kinesin-1 motor
domain implicated in binding to microtubules [56]. Phosphorylation of serine 176 by JNK3 reduces kinesin-1 binding to
microtubules and inhibits kinesin-1 translocation along axonal
microtubules in vivo [26]. To determine whether phosphorylation
of kinesin-1 by p38 had a similar effect, GFP-tagged, kinesin-1
constructs were expressed in cultured hippocampal neurons to
evaluate effects of dual S175/S176 phosphorylation on kinesin-1

Conventional kinesin is a novel p38a substrate
To determine how p38 affected anterograde FAT we analyzed
downstream targets of activated p38. Given that JNK3, a MAPK
that is biochemically similar to p38a MAPK [55], phosphorylates
kinesin-1, we tested phosphorylation of kinesin-1 by p38a. In vitro
kinase assays showed that recombinant p38a phosphorylates both
PLOS ONE | www.plosone.org
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Figure 4. Activation of p38 MAPK by pathogenic SOD1 in axoplasm and mouse spinal cord. (a) Immunoblots with phosphoantibodies
show activation of p38 (p-p38) in axoplasms perfused with G93A-SOD1 (G93A), compared to WT-SOD1 (WT). No changes were found in activities of
GSK3 (p-GSK3), JNK (p-JNK) or ERK (p-ERK) with perfusion of SOD1. An SOD1 antibody confirmed that similar levels of WT-SOD1 and G93A-SOD1 were
perfused, and kinesin-1 (KHC) antibodies serve as a loading control for axoplasmic protein. Representative results from three independent
experiments (Squids 1–3) are shown. (b) Quantitation of blots reveals a 3–4 fold increase in p-p38 with G93A SOD1, compared to WT-SOD1 (n = 8;
p#0.05 (#) by a t-test). No significant differences were found in levels of activated GSK3 (n = 3) or ERK (n = 3) (c) Increased activation of p38, but not
ERK was also seen in axoplasms perfused with G85R-SOD1 (G85R) polypeptides. (d) Phosphorylation of both neurofilaments (NF) and p38 MAPK was
analyzed in spinal cords of age-matched (50 days old) non-transgenic (Naı̈ve), human WT-SOD1 (WT) transgenic and human G93A-SOD1 (G93A)
transgenic mice using phosphorylation sensitive antibodies. Kinesin heavy chain (KHC) blots show similar levels of protein loading. SMI32 antibodies
recognize a dephosphorylated epitope in NFH that can be phosphorylated by MAPKs, whereas SMI31 recognizes an epitope not affected by
phosphorylation with MAPKs [34]. SMI31 immunoreactivity showed similar levels in all mice and serves as a second loading control. In contrast, SMI32
reactivity is reduced in G93A-SOD1 mice, but not naı̈ve and WT-SOD1 mice, suggesting increased phosphorylation of NFs by MAPKs in FALS.
Accordingly, p38 activity (p-p38) was increased in spinal cord of G93A-SOD1 mice, with a slight activation in WT-SOD1 mice.
doi:10.1371/journal.pone.0065235.g004

accumulated at axon tips did not differ significantly from KHC559GFP-WT (8868% vs. 92610%, respectively, mean 6 SEM)
(Fig. 8g). In contrast, much lower levels of phosphomimetic
KHC559-GFP-S175E/S176E construct accumulated at axonal
tips, compared to KHC559-GFP-WT construct (1969% vs.
92610%, respectively, mean 6 SEM; t-test, p,0.001). KHC559GFP- S175E/S176E fluorescence was prominent in cell bodies
with faint staining of neurites (Fig. 8e). Effects of double
pseudophosphorylation were more dramatic than those with
S175E single pseudophosphorylated KHC559 [26]. Thus, a
mutation mimicking Ser175/176 phosphorylation dramatically
reduces efficiency of kinesin-1 translocation along axonal microtubules in cultured neurons.

motility in vivo (Fig. 8). These were co-expressed with soluble
tdTomato to define axonal and dendritic processes [26] (Fig. 8b, d,
f). A GFP-tagged kinesin-1 construct encompassing the first 559
amino acids of kinesin-1C (KHC559-GFP -WT) selectively
translocates and accumulates at distal ends of axons, but not
dendrites [26,57]. Little or no fluorescence from KHC559-GFPWT was detected in cell bodies or along axons, suggesting highly
efficient translocation along axonal microtubules (Fig. 8a). We
compared translocation of KHC559-GFP-WT (Fig. 8a) with that of
the phosphomimetic construct KHC559-GFP-S175E/S176E
(Fig. 8e), and the non-phosphorylatable control construct
KHC559-GFP-S175A/S176A (Fig. 8c). Using quantitative fluorescence microscopy the amount of KHC559-GFP-S175A/S176A
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Figure 5. Increased Phospho-p38 in ventral horn of lumbar spinal cord in presymptomatic G93A-SOD1 mice. Spinal cords from 60 days
old naı̈ve nontransgenic mice (endogenous) and transgenic mice overexpressing either human WT- or G93A-SOD1 were analyzed by
immunohistochemistry for cellular distribution of activated p38 MAPK. (a–c) Low magnification (10X objective) images of lumbar spinal cord
double-labeled with a neuronal marker (NeuN, in green) and activated p38 MAPK (pP38, in red). (d–f) Higher magnification images (256objective) of
ventral horns. In naı̈ve mice spinal cords with only endogenous mouse SOD1 (a, d), neurons are readily visible in the both dorsal and ventral horns
(green), but p38 MAPK activity (red) is low with a few neurons positive for both markers (yellow), primarily in the dorsal horn. In transgenic WT-SOD1
spinal cord (b, e), neuronal staining is comparable to naı̈ve mice, but p-p38 immunoreactivity clearly increases in regions with minimal NeuN staining,
suggesting increased p38 MAPK activation in glia. In G93A-SOD1 spinal cord (c, f),p-p38 immunoreactivity is much higher in both white and grey
matter regions,. An increase in pP38 co-localization with NeuN, is consistent with activation of p38 MAPK in neurons. (g–i) Semi-quantitative
fluorescence analysis of high magnification sections shows an increase in co-localization of pP38 and NeuN immunoreactivity with G93A-SOD mice
(n = 9 for all conditions). (g) Pearson’s correlation coefficient (PCC) (showing co-localization, but not intensity levels) of NeuN and pP38 significantly
increased in both transgenic mice relative to naı̈ve mice, not quite rising to significance between naı̈ve and WT-SOD1 (p = 0.058). In G93A-SOD1 mice,
PPC values were significantly increased over both naı̈ve and WT-SOD1 mice (p,0.0001). (h) To address relative levels of pP38 immunoreactivity, we
compared red pixels/area. The difference between naı̈ve and WT-SOD1 mice was not significant, but G93A-SOD1 mice was significantly different from
both naı̈ve and WT-SOD1 mice at p#0.0001 (#) (i) An increased ratio of pP38/NeuN (R/G ratio) for G93A-SOD1 mice suggests that mutant SOD1
activates p38 in neurons. Differences between G93A-SOD1 and both naı̈ve and WT-SOD1 mice were significant at p#0.005 (#).
doi:10.1371/journal.pone.0065235.g005
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Figure 6. Active p38a mimics the effects of pathogenic SOD1 on anterograde FAT. Effects of active, recombinant p38 isoforms on FAT
were evaluated using vesicle motility assays in isolated squid axoplasm. P38a and P38b were perfused at a constant specific activity based on in vitro
kinase assays with the ATF-2 substrate. (a) Perfusion of active p38a in axoplasm selectively inhibited anterograde FAT, as did pathogenic SOD1
(compare to Fig. 1b-d). (b) Unlike p38a, p38b inhibited both anterograde and retrograde FAT. (c) Quantitation of values obtained between 3050 minutes shows that p38a most closely mimicked effects of pathogenic SOD1, suggesting this isoform mediates the effects of mSOD1 on FAT in
axoplasm (#: difference significant from WT-SOD1 at p,0.01 by t-test).
doi:10.1371/journal.pone.0065235.g006

Synthetic DVD peptides block p38 activation by inhibiting the
docking and activation of MKKs by a subset of MKKKs,
including MEKKs, ASK, TAO and TAK1 [60]. A DVD peptide
containing a mutation that abolishes its blocking activity served as
control [60]. Significantly, DVD peptide blocked effects of both
G93A-SOD1 and oxidized WT-SOD1 on FAT (Fig. 9a,c),
whereas control DVD peptide had no protective effect (Fig. S6).
In contrast, pharmacological inhibition of mixed lineage kinases
(MLK) by CEP11004 [61] failed to prevent G93A-SOD1 effects
on FAT, suggesting that activation of axonal p38 by mSOD1 and
oxidized SOD1 involves an MKKK upstream of p38 other than
MLKs (Fig. 9b) [46].

SOD1 activates MAPKs upstream of p38
To address mechanisms for activation of p38 by mSOD1, we
looked at the role of upstream MAPK kinases. Activation of p38
involves phosphorylation by MAPK kinases (MKK3 and MKK6),
which in turn are activated by MAPK kinase kinases (MKKKs)
[58]. Members of several MKKK families can activate p38,
including mixed-lineage kinases (MLKs), MEK kinases (MEKKs),
apoptosis-inducing kinase (ASK1), TGFb-activated kinase 1
(TAK1) and Thousand And One amino acids kinases (TAOs)
[50,58,59]. Oxidized WT SOD1, SOD1 from SALS patients [23]
and mSOD1 had similar effects on anterograde FAT and p38
MAPK activity, prompting us to ask whether they activate p38
MAPK by activating kinases upstream of p38. We co-perfused
G93A-SOD1 or oxidized WT SOD1 with DVD peptide.

Figure 7. Active p38a directly phosphorylates kinesin-1 at serines 175–176. (a) Recombinant p38a was incubated with c-32P-ATP in the
presence (+) or absence (–) of a recombinant protein construct comprising the first 584 amino acids of kinesin-1 (KHC584). Coomassie blue staining of
gels shows the position of KHC584 and p38a. Autoradiogram (32P) shows 32P incorporation into KHC584 (asterisk), as well as autophosphorylation of
p38a (arrowhead). (b) Mass spectrometry studies identified a peptide within the motor domain of kinesin-1 (amino acids 174–188) showing
unequivocal evidence of phosphorylation by p38a. Tandem mass spectrometry analysis (MS/MS) by collision-induced dissociation further mapped
phosphorylation on both Ser175 and Ser176 (grey box). (c) Sequence alignment shows that serines 175 and 176 (grey box) are conserved among
human, mouse and squid sequences for kinesin-1.
doi:10.1371/journal.pone.0065235.g007
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Figure 8. Pseudophosphorylation of kinesin-1 at S175/S176 inhibits movement of kinesin-1. To determine the effects of modifying S175
and S176 on kinesin-1function, recombinant GFP-tagged kinesin (KHC559) was modified to preclude phosphorylation at these sites (S175AS176A) or
to mimic phosphorylation (S175ES176E). (a–f) Stage 3 hippocampal neurons were examined 5 h after co-transfection with GFP-tagged KHC559
constructs and a tdTomato construct, which diffuses throughout the cell and allows visualization of neurites (b, d, f). Both wild-type kinesin-1
(KHC559 WT, a) and a non-phosphorylatable mutant (KHC559 S175A/S176A, c) accumulated efficiently at axonal tips (labeled by arrows) with minimal
steady-state labeling of cell bodies (arrowheads). In contrast, pseudophosphorylated mutant KHC559 S175E/S176E, e) was mainly present in neuronal
cell bodies. Quantitative immunofluorescence analysis shows fraction of total KHC559 fluorescence at axon tips for all constructs (g). Far less
phosphomimicking KHC559 S175E/S176E constructs accumulated at axon tips than KHC559 WT or KHC559 S175A/S176A (#: p,0.001; n: 27–43 cells per
condition). Bars show mean and standard deviation. Scale bar = 20 mm.
doi:10.1371/journal.pone.0065235.g008

synapses and impairments in FAT, among others [1]. However,
distinguishing between primary pathognomonic events in ALS and
secondary consequences of primary mechanisms has proven
difficult [7]. In ALS, motor neurons typically degenerate following
a ‘‘dying-back’’ pattern, characterized by altered synaptic function
and axonal connectivity well before cell death [6,65,66]. Genetic
data indicates that deficits in anterograde FAT suffice to produce
dying-back degeneration of motor neurons [29], suggesting that
FAT deficits might constitute a critical pathogenic event in ALS
[7]. However, specific molecular components and mechanisms
linking pathogenic mSOD1 to deficits in FAT were unknown.
Vesicle motility assays in isolated axoplasm allowed direct
evaluation of mSOD1 effects on FAT independent of nuclear
activity, transcription and glial-related effects. WT-SOD1 had no
effect on FAT when perfused in axoplasm, but all FALS-linked
SOD1 mutants tested (G93A, G85R and H46R) selectively
inhibited anterograde, kinesin-based FAT (Fig. 1). Thus, inhibition
of anterograde FAT represents a common toxic effect of both
FALS-related mSOD1 (Fig. 1) and misfolded wild type SOD1
[23,46]. G93A-SOD1 has wild-type-like SOD1 dismutase and
metal binding activity, whereas G85R and H46R mutants are
catalytically deficient, indicating that inhibition of FAT by FALSlinked mutants is unrelated to normal enzyme functions [67].
Selective inhibition of anterograde, but not retrograde FAT in
axoplasm by pathogenic SOD1 proteins ruled out deleterious
effects on microtubules, ATP availability, or general steric
interference of motor proteins by mSOD1. Consistent with a
prior report [28], no interaction was observed between SOD1 and

Discussion
Some 145 different mutations in SOD1 are linked to FALS
(http://alsod.iop.kcl.ac.uk/), accounting for roughly 20% of FALS
cases. The characteristic pathological features of ALS are
remarkably similar whether the disease is FALS or SALS,
including axonal degeneration, abnormal patterns of phosphorylation, and FAT defects. In mSOD1-related FALS, pathogenic
mutations are distributed throughout the molecule with diverse
effects on enzymatic activity [62], suggesting that loss of SOD1
function is not a primary factor to mSOD1 pathogenesis. Analysis
of the genetics and biochemistry of mSOD1 transgenic mice and
human FALS indicated that pathogenic effects of FALS-linked
mSOD1 in motor neurons represent a toxic gain of function [1],
but the nature of this gained function was unclear.
An important step in defining pathogenic mechanisms for any
disease is identification of pathognomonic features of the disease.
Many ALS studies focus on mechanisms of motor neuron cell
death, which occur through well-defined apoptotic pathways
[63,64]. However, death of motor neurons can be prevented
without significantly altering the course of the disease [65,66].
Early neurological symptoms of ALS relate better to loss of
synaptic function and axonal connectivity than motor neuron cell
death, which is a much later event in ALS [66]. However, both
molecular events might be linked to abnormal activation of the
p38 MAPK pathway by pathogenic SOD1 (Fig. S7).
Neurons affected in FALS exhibit a number of distinctive early
changes, including abnormal activation of protein kinases,
aberrant patterns of neurofilament phosphorylation, loss of
PLOS ONE | www.plosone.org
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that FALS mutant SOD1 and misfolded WT-SOD1 activate a common
p38 MAPK pathway [23].
doi:10.1371/journal.pone.0065235.g009

kinesin in spinal cord from transgenic mice expressing WT-SOD1
or G93A-SOD1 (Fig. 1f).
Conventional kinesin and cytoplasmic dynein are regulated by
phosphorylation of specific motor subunits. Abnormal activation
of protein kinases and aberrant patterns of protein phosphorylation represent major ALS hallmarks [9]. Our previous studies in
axoplasm suggested that pathogenic SOD1 might activate kinases
involved in regulation of kinesin-based FAT [29]. Pharmacological, biochemical and immunochemical approaches indicated a
role for p38 MAPK in inhibiting anterograde FAT (Figs. 3–7).
Previous studies had demonstrated the presence of both p38a and
p38b MAPK in neurons, with localization in both nuclei and
cytoplasmic domains [68]. Activation of p38 MAPK has also been
associated with axonal pathology [47,69], but the p38 isoform was
not determined and the axonal target of activated p38 MAPK was
unknown [9]. Identification of kinesin-1 motor domains as a novel
p38a kinase substrate provides a molecular basis for inhibitory
effects of FALS-linked SOD1 mutants on anterograde FAT (Figs 8,
and Fig. S8). Our findings were consistent with studies showing
activation of p38 MAPK in motor neurons as an early pathogenic
event in ALS [47,51] and other reports showing that p38a may be
enriched in neurons, whereas p38b was higher in microglia [70].
In mammals, expression of p38a (MAPK14) and p38b (MAPK11)
is higher in ventral motor neurons of adult mouse spinal cord than
in most cells of spinal cord and brain (Fig. S2), which may partially
explain the unique vulnerability of motor neurons to FALS-linked
mutants of SOD1, despite near ubiquitous expression of SOD1. In
addition, transgenic mice expressing G93A-SOD1 exhibit significant activation of p38 MAPK in neuronal cells (Fig. 5). Curiously,
p38 MAPK was slightly activated in spinal cords of mice
overexpressing WT-SOD1, but this was primarily in white matter,
presumably in glia and other non-neuronal cells.
The full complement of p38 isoforms in isolated axoplasm
remains to be determined. Thus, selective inhibition of anterograde FAT by mSOD1 in squid axoplasm may result from either
selective activation or selective expression of p38a In mammalian
motor neurons, both p38 isoforms are expressed (Fig. 6) [68] and
thus it is conceivable that mutant SOD1 may activate both a and
b isoforms of p38 MAPK in mammals, ultimately affecting both
anterograde and retrograde axonal transport. Regardless, the
relative contributions of retrograde and anterograde FAT deficits
to FALS pathogenesis in humans remains to be fully characterized.
In isolated axoplasms, kinesin-1 and cytoplasmic dyneindependent FAT were evaluated directly by measuring the rate
and amount of MBOs moving in both directions after challenge
with FALS-linked mSOD1 (Figs. 1 and 3). Moreover, our studies
identified differential isoform-specific effects of p38 on FAT, with
p38a selectively inhibiting anterograde FAT and p38b affecting
both directions (Fig. 6). Regardless of p38 isoforms involved,
inhibition of FAT by SOD1 is likely to differentially affect specific
kinesin-1 isoforms and MBO cargos. Different kinesin-1 isoforms
move different MBOs [24,71] and kinesin-1 isoforms may differ in
sensitivity to p38 (unpublished data). A recent study found no
correlation between changes in mitochondrial transport and
axonal degeneration in mouse models of FALS [72], but,
mitochondrial transport differs significantly from other FAT
cargoes [73,74], such as MBOs carrying synaptic vesicle precursors [35,75,76].

Figure 9. Inhibition of anterograde FAT induced by mSOD1
depends on specific MKKK-MKK interactions. Co-perfusion of
G93A-SOD1 with DVD peptide (a), but not with the Mixed-Lineage
Kinase inhibitor CEP11004 (b), prevents inhibition of FAT induced by
G93A-SOD1. DVD peptide prevents activation of MKKs by some MKKKs
(n = number of axoplasms) [60]. These data suggest that the activation
of p38 and the inhibition of FAT induced by G93A-SOD1 involves
activation of one or more MAPKKKs other than MLKs. (c) The DVD
peptide also blocks inhibition of FAT by oxidized WT-SOD1 suggesting
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vertebrate animals or human embryonic cell lines were used at
other sites. All studies were conducted at institutions in the USA.

The selective effect of mSOD1 on anterograde, but not
retrograde FAT in isolated axoplasm was unexpected, given
reports describing inhibition of both anterograde and retrograde
FAT in G93A-SOD1 mice [14,28,53,54]. Some reports were
based on reduced accumulation of FAT membrane proteins at a
nerve ligation [14,54]. Although informative, evaluation of
retrograde FAT by this method could be affected by reductions
in delivery of cargoes by anterograde FAT, and/or by reductions
in synaptic activity leading to reduced commitment of material to
retrograde FAT. Further, these experiments were performed in
mice that were 85 days [54] and 133 days old [14], ages at which
major denervation has occurred [6]. Reduced delivery of
retrogradely transported cargoes has important implications for
neuronal survival, but nerve ligation experiments do not directly
evaluate changes in motor protein function.
Suggestions of a role for retrograde FAT deficits in prior FALS
studies [54,77–79] also stem from genetic studies reporting motor
neuron degeneration in mice with some cytoplasmic dynein heavy
chain mutations (i.e. Legs at odd angles (Loa), and Cramping 1 (Cra1),
but not Sprawling [80]). Subsequent studies showed that Loa and
Cra1 mutants exhibit severe proprioceptive sensory neuron loss
before any loss of motor neurons [81], raising concerns on the use
of these mice as models of motor neuron disease [82]. Curiously,
some dynein mutations extended FALS mutant transgenic mouse
lifespan [83,84], while other mutations did not [85]. Collectively,
genetic evidence demonstrated that specific perturbations in
cytoplasmic dynein-dependent retrograde FAT may result in
peripheral sensory neuropathy, but inhibition of retrograde FAT
alone might not be sufficient to produce motor neuron disease
[86].
In summary, FALS-linked mSOD1 activates a p38 MAPK
pathway in squid axoplasm and mammalian spinal cord, which in
turn phosphorylates kinesin-1 motor domains leading to reduced
ability of kinesin-1 to move along axonal microtubules (Fig. 8 and
Fig. S8). Disruption of FAT leading to loss of synaptic function and
dying–back axonopathy establishes mSOD1-linked FALS as a
dysferopathy, i.e. a pathology associated with compromised fast
axonal transport leading to a late-onset dying back neuropathy
[29,87], resulting in this case from aberrant signaling through the
p38 pathway. Clearly, p38 MAPK has substrates other than
kinesin-1, including neurofilaments and proteins involved in
transcription or proapoptotic pathways (Fig. S8). Alterations in
the phosphorylation of multiple p38 targets may contribute in
significant ways to ALS pathology [88]. Therefore, targeting
signaling pathways between mSOD1 and p38 represent a
promising new direction for therapeutic intervention in ALS,
particularly since this pathway is also implicated in some SALS
cases [23], and brain-permeable p38 kinase inhibitors exist [45].

Antibodies and Reagents
The following antibodies were used: anti-KHC (H2 clone) [24],
anti-SOD1 (D3H5 clone, a generous gift from Dr. Jean-Pierre
Julien), SMI31 and SMI32 antibodies (Sternberger), anti-phospho
JNK (Cell Signaling #9252), anti-phospho p38 (Cell Signaling
#9215), anti-phospho GSK3 (Santa Cruz #11757), anti-phospho
ERK (Santa Cruz #7383). The secondary antibodies used were
Jackson 111–035–045 HRP-conjugated goat anti-rabbit, Jackson
115–035–146 HRP-conjugated goat anti-mouse IgG, and Jackson
805–035–180 HRP-conjugated bovine anti-goat IgG. Primary
antibodies for immunohistochemistry were anti phospho p-38
MAPK (pP38) (Cell Signaling cat#4511) and anti- NeuN (Novus
Biological cat# NBP1-9269). Secondary antibodies were goat
anti-rabbit Alexa 594 (Invitrogen cat# A11012) and anti-mouse
Alexa 488 (Invitrogen cat# A11011). Cyclosporine A, SB203580
and SP600125 (JNK inhibitor II) were obtained from Calbiochem.
CEP11004 was a gift from Cephalon. MW01-6-189WH (MW189)
and MW01-2-069SRM (MW069) are described in [45]. Histagged KHC584 protein constructs were expressed in BL21-Codon
Plus (DE3) E. coli (Stratagene), and purified using Talon beads
(Clontech), as before [26]. Recombinant p38 isoforms were from
Upstate (p38a #14–251, p38b #14–253). Recombinant SOD1
constructs were prepared in insect cells as before [21].

Vesicle motility assays in isolated axoplasm
Axoplasms were extruded from giant axons of the squid Loligo
pealii (Marine Biological Laboratory) as described previously [19].
Recombinant proteins, peptides or inhibitors were diluted into X/
2 buffer (175 mM potassium aspartate, 65 mM taurine, 35 mM
betaine, 25 mM glycine, 10 mM HEPES, 6.5 mM MgCl2, 5 mM
EGTA, 1.5 mM CaCl2, 0.5 mM glucose, pH 7.2) supplemented
with 2–5 mM ATP (Figs. 1, 3, 6) and 20 ml added to perfusion
chambers. For biochemical experiments in isolated axoplasm, a
mixture of 1mM ATP and 0.1 mCi 32P-labelled ATP was used.
For vesicle motility assays, preparations were analyzed on a Zeiss
Axiomat with a 1006, 1.3 n.a. objective, and DIC optics.
Hamamatsu Argus 20 and Model 2400 CCD camera were used
for image processing and analysis. Organelle velocities were
measured with a Photonics Microscopy C2117 video manipulator
(Hamamatsu) as described previously [38]. For quantitative
comparisons between conditions, velocity measurements taken
30–50 minutes after perfusion were pooled and the mean
velocities calculated. Rates obtained by this method reflect a
sampling of vesicle movements in and out of the plane of focus.
Therefore, recorded velocities correlate with both rate and number
of vesicles moving in a given treatment (i.e. low transport rates
may reflect reduced number of vesicles moving, as well as slower
velocities [19,38,89]}.

Materials and Methods
Ethics Statement

Immunochemical methods

All animal work was done according to guidelines established by
the NIH and the corresponding institutions and are covered by
appropriate institutional animal care and use committee protocols
from the University of Illinois at Chicago Animal Care Committee
(approval #11–201, and #11–180) and Oregon Health Sciences
University Institutional Animal Care and Use Committee
(approval #A607)). There were no primates or human subjects
involved in any of these studies, so these experiments are not
eligible for consideration by Institutional Review Boards for
protection of human subjects. The animal care and use
committees at UIC and OHSU are responsible for evaluating all
ethical and welfare issues regarding vertebrate animals. No
PLOS ONE | www.plosone.org

Spinal cords from transgenic mice expressing WT-SOD1 and
G93A-SOD1 were homogenized in lysis buffer (LB; 25 mM Tris
pH 7.4, 150 mM NaCl, 1% Triton X-100, and mammalian
protease inhibitor cocktail (Sigma, 1/100 dilution) as described
previously [24]. Quantitative immunoblots were performed as
described previously [26] using SDS-PAGE on 4–12% Bis-Tris
gels (NuPage minigels, Invitrogen), using MOPS Running Buffer
(Invitrogen) and transferred to PVDF using Towbin buffer
supplemented with 10% (v/v) methanol. Orthovanadate (1 mM)
and Sodium Fluoride (10 mM) were in all incubation steps
involving phosphoantibodies. Primary antibody binding was
11
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detected with HRP-conjugated anti-mouse, anti-rabbit or antigoat antibodies (Jackson Immunoresearch), and visualized by
chemiluminescence (ECL, Amersham).

and a differential search for serine, threonine and tyrosine
phosphorylation. The dataset was filtered using INTERACT
based on the following criteria: delta correlation of 0.1, and X
correlation values for +1 peptides $1.8,+2$2.15 and +3$3.2.

Immunohistochemistry
Kinesin-1 Translocation Assays

Experiments followed approved Institutional animal protocols
at the University of Illinois in Chicago. Sixty day old transgenic
WT-SOD1 (JAX#002297, 3 Female), G93A-SOD1 (JAX
#002726, 2 female and 1 male) mice, and nontransgenic
littermates (3 male) were euthanized by carbon monoxide
inhalation, and transcardially perfused with PBS and 4% solution
of paraformaldehyde (PFA) in PBS. Tissues were process for
sectioning and embedded in OCT (Tissue Tek, cat #4583) 50 mm
thick spinal cord sections were obtained and mounted on slides.
OCT was removed and sections permeabilized with Triton-X100.
Primary antibodies were anti phospho p-38 MAPK (pP38) (1:200)
and anti- NeuN (1:400). Secondary antibodies were goat antirabbit Alexa 594 and anti-mouse Alexa 488 used at 1:1000
dilution. Slides were dried and mounted in VectaShield mounting
media (Vector Laboratories, Burlingame, CA) and sealed with nail
varnish.
Spinal cord images such as those in Fig 5 were assembled from
images obtained with a 106 objective. For quantitation of pP38
immunoreactivity (Fig. 5 h–i), images of the spinal cord ventral
horn were obtained using a 25X objective (n = 3 animals per
group). Red and green channels (phospho-p38 MAPK and NeuN,
respectively) were transformed to 8 bit images using ImageJ
software (http://imagej.nih.gov/ij/) and mean pixel values per
equal area on each image quantified by auto-threshold methods
(Fig. 5h). In order to determinate relative pP38 levels in NeuNpositive cells, an index; pP38/NeuN was generated (Fig. 5i). Colocalization index values represented by the Pearson’s correlation
values were obtained using the co-localization finder toolbox in
ImageJ. [90] (Fig. 5g).

S175A/ S176A and S175E/ S176E mutant variants of rat GFPtagged KIF5C559 constructs were prepared by site-directed
mutagenesis. Experiments evaluating the accumulation of these
constructs were performed as before [57]. Primary hippocampal
cultures with glial feeder layers were prepared from E18
embryonic rats. After 2 days in culture, hippocampal neurons
were co-transfected with plasmids pBA-KIF5C559WT-GFP (Jacobson et al., 2006), pBA-KIF5C559S175A/176A-GFP, or pBAKIF5C559S175E/176E-GFP together with soluble tdTomato protein
using Lipofectamine 2000 (Invitrogen, Carlsbad, California). Five
hours after transfection, cells were fixed with 4% paraformaldehyde. Fluorescence images were taken using a Zeiss Axio Observer
Z1 microscope (Carl Zeiss, Thornwood, NY). To determine
fraction of KIF5C559 signal at axon tips, the integrated fluorescence intensity of the whole cell and the distal axon were
calculated after subtracting background using Metamorph software (Molecular Devices Corporation, Downingtown, PA).

Statistical Analysis
All experiments were repeated at least 3 times. Unless otherwise
stated, the data was typically analyzed by pooled t-test of m1–m2
using DataDesk statistical software. Quantitative data was
expressed as mean 6 SEM unless otherwise stated and significance
was determined at p,0.05 or 0.01 as noted. P values are given as
calculated.

Supporting Information
Text S1 Supplementary Results and Methods. Supplemental results are provided showing the expression of p38 MAP
kinase a and b in the adult mouse spinal cord, indicating that these
kinases are highly expressed in ventral motor neurons. Results of
experiments showing that activation of p38 MAP kinases by
mutant SOD1 compromises cell viability as well as axonal
transport, providing a link between this pathway and the loss of
motor neurons in SOD1-related ALS. An expanded description of
the methods used in this study is provided to facilitate future
studies.
(DOCX)

In vitro Phosphorylation
In vitro phosphorylation experiments (40 ml volume) were
performed by incubating KHC584 protein constructs (3 mM) with
0.1?M p38a in HEM buffer (50 mM HEPES, 12 mM MgSO4,
100 mM ATP pH 7.4), as previously described [26].

Mass spectrometry studies
Phosphorylated KHC584 protein was subjected to in solution
trypsin digestion for LC/MS/MS analysis as described previously
[26]. Briefly, dried samples were resuspended in 30 mM HEPES
and 30 mM NaF in the presence of 1 mg of trypsin (Sigma,
proteomics grade) and incubated at 37uC overnight (16–18 h).
The resulting peptides were later resuspended in buffer A (5%
acetonitrile, 0.4% acetic acid, 0.005% heptafluorobutyric acid
(vol/vol) in water) for mass spectrometry analysis. Samples were
analyzed by high-pressure liquid chromatography (HPLC, 11-cm
by 100-mm fused silica capillary column packed with reverse C18
material, Magic beads, Michrom Bioresources) on line with a
LTQ (a two-dimensional ion trap) instrument equipped with a
commercial nano-electrospray source (Thermo Finnigan). Samples
were automatically loaded by a microautosampler (Famos, LC
Packings). Samples were analyzed by performing full scan followed
by tandem mass spectrometry or MS/MS of the five most intense
ions (top five) by collision-induced dissociation. Sample loading,
solvent delivery and scan function were controlled with Xcalibur
software (Thermo Finnigan). LC/MS/MS files were searched
using a SEQUEST algorithm against a database containing
KIF5C_Rat and KIF5C_Mouse, among others proteins. SEQUEST search parameters included mass tolerance of 61.5 Da,
PLOS ONE | www.plosone.org

Figure S1 Outline of metabolic labeling experiments
and immunobloting analysis in isolated squid axoplasm.
Two giant axons were dissected from the same squid (‘‘sister’’
axons), extruded, placed on glass coverslips, and incubated with
recombinant SOD1 proteins. One axon was perfused with WTSOD1, whereas the contralateral axon was perfused with
pathogenic SOD1. For metabolic labeling experiments in
Figure 2, an aliquot of radiolabelled 32P-ATP was added to each
axoplasm. After a 50-minute incubation, axons were lysed and
processed for autoradiography (Fig. 2) or immunoblotting (Fig. 4).
(TIF)
Figure S2 Expression of p38a/MAPK14 and p38b/
MAPK11 in spinal cord is enriched in ventral motor
neurons. Data from the Allen Mouse Spinal Cord Atlas (http://
mousespinal.brain-map.org/) shows expression of p38 MAPK a
and b isoforms of the lumbar spinal cord of an adult mouse. Based
on location, Nissl staining and somal size, the large cells in the
ventral horn are identified as alpha motor neuron cell bodies (see
12
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arrowheads for examples). The panels are (a) in situ hybridization
of a section of lumbar spinal cord from an adult mouse showing
that distribution of p38a/MAPK14 mRNA is enriched in the
cytoplasm of large neurons, particularly in motor neurons of the
ventral horn; and (b) expression mask derived from the in situ
data shows differential expression of the target gene (p38a/
MAPK14) with black reflecting no detectable expression, blue
showing low expression with green and yellow representing
increasing levels of expression. (c) In situ hybridization of a section
of lumbar spinal cord in an adult mouse showing that p38b/
MAPK11 mRNA also exhibits higher expression in large cells in
the ventral horn, presumptive alpha motor neurons; and (d)
expression mask showing differential expression of the target gene
(p38b/MAPK1). Both p38a and p38b are preferentially expressed
in motor neurons.
(TIF)

conserved between human, mouse and squid kinesin-1 protein
were S175/S176 in peptide 173–190 (shown in red). (b) Several
parameters are shown for the identified phosphopeptides. From
left to right: File name of the mass spectrum obtained from the
mass spectrometer for the peptide, total mass of the ion or peptide,
x correlation (XCorr) and delta correlation value (dCn) for each
identified peptide. These two parameters emerge from the
bioinformatic data analysis after mass spectrometry. These values
are used to decide whether a peptide should be reported or not.
The cut off values were specified in materials and methods (see
above). The next two columns indicate the number of identified
peptide during CID and the total number of theoretical ions.
Finally, the protein name entry in the database and the peptide
sequence are given.
(TIF)
Figure S6 DVD Peptide Prevents Inhibition of FAT by
mutant SOD1. Co-perfusion of G93A-SOD1 with DVD peptide
(a), but not with a control DVD peptide (b) prevents inhibition of
FAT induced by G93A-SOD1. DVD peptide prevents activation
of MKKs by some MKKKs (n = number of axoplasms), whereas
DVD control peptide does not. These data suggest that the
activation of p38 and the inhibition of FAT induced by G93ASOD1 involve activation of one or more MAPKKKs that require
the DVD docking motif for activation of downstream kinases.
(TIF)

Figure S3 Recombinant p38a directly phosphorylated

both recombinant KHC and immunoprecipitated endogenous brain KHC. (a), Recombinant p38a was incubated
in the presence (+) or absence (–) of KHC (KHC584) recombinant
protein. An autoradiogram shows incorporation of 32P into
KHC584 (*) and autophosphorylated JNK. (b), Recombinant
p38a was incubated with immunoprecipitated, endogenous mouse
brain kinesin-1. The autoradiogram (32P) shows increased
phosphorylation of KHC. The accompanying western blot (WB)
shows equal amounts of immunoprecipitated KHC in each
condition.
(TIF)

Inhibition of p38 attenuates mSOD1-induced
apoptosis. Expression of mutant SOD1 in N2A cells has a very
modest effect on cell viability that is greatly enhanced by challenge
with cyclosporine A (CsA). Stably transfected N2A cells expressing
WT-SOD1 (WT-SOD1, left panels) or G85R-SOD1 (mSOD1,
right panels) were incubated with various concentrations of CsA,
(0 to 14 mg/ml) in the presence (+) or absence (–) of the p38
inhibitor SB203580 (10 mM). (a) LDH toxicity assays show a dosedependent increase in CsA-induced cytotoxicity on both WTSOD1 and mSOD1 cell lines. However, the toxic effect of CsA is
more pronounced in cells expressing mSOD1 (hatched red bars),
compared to cells expressing WT-SOD1 (black striped bars).
Remarkably, treatment of mSOD1 N2A cells with the p38
inhibitor SB203580 significantly attenuated cell death at 0, 3.5 and
7 mg/ml CsA (solid bars). In contrast, SB203580 reduced CsAinduced toxicity at 7 mg/ml, but not 3.5 mg/ml (solid bars) in WTSOD1 N2A cells. Data represent the mean 6 SEM % cytotoxicity
for n = 8 wells (* p,0.0001). (b) Caspase-Glo assays confirmed
and extended results in a, showing that CsA induced the activation
of the pro-apoptotic caspases 3 and 7 in mSOD1 N2A cells (red
hatched bars) to a greater extent than WT-SOD1 N2A cells (black
striped bars). Treatment of mSOD1 N2A cells with SB203580
(solid bars) significantly attenuated caspase 3/7 activation, whereas
WT-SOD1 cells exhibited similar caspase activity levels in the
presence (solid bars) and absence (striped black bars) of SB203580.
Data represent the mean 6 SEM luminescence signal for treated
cells relative to untreated cells for n = 4 wells (* p,0.0001). These
results suggest p38 activity contributes to the increased vulnerability of mSOD1 N2A cells to CsA-induced cell death.
(TIF)
Figure S7

Figure S4 Mass spectrometry analysis of kinesin-1
phosphorylation by p38a. (a) Diagram of mass spectrometry
procedures for the analysis of kinesin-1 phosphorylation by p38a
showing the path that a protein sample follows during High
Performance Liquid Chromatography Mass spectrometry analysis
(HPLC-MS. Peptides generated by trypsin treatment of samples
are first resolved by a reversed phase column. After peptides elute
from the column, ions for mass spectrometry analysis are
generated by Electrospray Ionization (ESI). Once peptides enter
the mass spectrometer, the most abundant ions are individually
selected and captured to go under Collision Induced Dissociation
(CID), which yields a collection of shorter sequences for peptide
identification. The output of each individual peptide analysis is a
mass spectrum that is analyzed by bioinformatics to match to a
known protein in the database for protein identification. (b) Actual
mass spectrum of the KIF5c 174–188 phosphopeptide. The graph
shows the output mass spectrum, obtained from the mass
spectrometer, for one of the identified peptides of the KIF5c
protein. The graph plots ion intensity versus mass to charge ion
ratio (M/Z) for b+ (red) and y+ (blue) ions that are the direct (N to
C terminus) and reverse (C to N terminus) ion series obtained
during CID. The identified amino acids peptide sequence for this
spectrum is shown in the upper right of the spectrum.
(TIF)
Figure S5 p38a phosphorylation sites on kinesin-1. (a)
The table shows the identified phosphopeptides in the KIF5c rat
sequence from recombinant KIF5c phosphorylated by p38a in
vitro. From left to right, the table shows the protein ID entry for
the database utilized in protein identification analysis; the
sequence of the identified phosphopeptide; the mass to ion charge
ratio that corresponds unequivocally to that ion or peptide;
peptide position in the sequences of the protein (KIF5c) given by
the position of the amino (N terminus) and carboxyl (C terminus)
amino acid residue; and the last column indicates the position of
the actual phosphorylated residue. Of these peptides, the only sites
PLOS ONE | www.plosone.org

Figure S8 Inhibition of conventional kinesin-based
motility induced by pathogenic SOD1. Our results showing
increased activation and phosphorylation of p38 by mSOD1
polypeptides suggest that these pathogenic mSOD1 polypeptides
activate specific MAPKKKs and MAPKKs (dashed arrow)
upstream of p38 (Fig. 9). Activation of axonal p38 would lead to
phosphorylation of kinesin-1, neurofilaments (NFs) and likely other
axonal substrates. Data in this work indicates that phosphorylation
13
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of kinesin-1 by p38 inhibits translocation of conventional kinesin
along microtubules. Reductions in the delivery of critical axonal
cargoes by conventional kinesin, (such as synaptic vesicle
precursors and organelles containing neurotrophin receptors)
would result in impaired synaptic function and dying-back
degeneration of neurons In addition, increased p38 activation in
neuronal cell bodies would be expected to promote alterations in
the activity of various transcription factors (i.e., ATF-2 and c-Jun,
among others), consistent with reports of transcriptional changes
and activation of apoptosis induced by pathogenic SOD1
expression.
(TIF)
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